Alpha Wealth Funds’s ProQR Therapeutics PRQR Stock Holding History

Alpha Wealth Funds’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$41.2K	Buy	+25,000	New	+$47.3K	0.02%	42

Other funds holding PRQR

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return

Franklin Street Advisors Chapel Hill, North Carolina $1.82B AUM 22.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

RFG Advisory Birmingham, Alabama $7.09B AUM 12.79% 1-Year Est. Return

AIM

Axiom Investment Management New York $121M AUM

Moody Lynn & Lieberson Boston, Massachusetts $1.93B AUM 20.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

WIA

Wetzel Investment Advisors Indianapolis, Indiana $290M AUM 16.64% 1-Year Est. Return

Alpha Wealth Funds's PRQR Position: Q3 2026 in Review

Alpha Wealth Funds opened a new position in ProQR Therapeutics (PRQR) in Q3 2026: 25,000 shares worth $41.2K. The stake represents 0.02% of the portfolio and ranks #42 among its holdings.

18 funds tracked by Wall St. Rank hold PRQR as of Q3 2026.

Alpha Wealth Funds held 25,000 shares of ProQR Therapeutics worth $41.2K as of Q3 2026.
ProQR Therapeutics was a new Alpha Wealth Funds position in Q3 2026.
ProQR Therapeutics made up 0.02% of Alpha Wealth Funds's portfolio in Q3 2026, its #42 holding.
18 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q3 2026.

Based on Alpha Wealth Funds's 13F filing for Q3 2026, filed 4 Nov 2026.